8-K: FDA Extends Review of Soleno Therapeutics' Prader-Willi Syndrome Drug, DCCR, by Three Months

The FDA has extended the review period for Soleno Therapeutics' DCCR drug for Prader-Willi Syndrome by three months, with a new target action date of March 27, 2025.

Summary

• The U.S. Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics' New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets.
• The drug is intended for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
• The new target action date is March 27, 2025, which is three months later than the original date of December 27, 2024.
• The FDA stated that responses to recent information requests constituted a major amendment to the NDA, necessitating the extension.
• The FDA did not raise any concerns regarding the safety, efficacy, or manufacturing of the drug.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the delay in the FDA review process, although the FDA did not raise any safety or efficacy concerns. The delay introduces uncertainty and pushes back the potential approval date.

Positives

• The FDA has not raised any concerns about the safety, efficacy, or manufacturing of DCCR.
• DCCR has received Breakthrough and Fast Track Designations in the U.S., and Orphan Drug Designation in both the U.S. and E.U.
• The drug has shown promise in addressing hyperphagia and other symptoms of PWS in clinical trials.
• The parent molecule, diazoxide, has been used for decades in other rare diseases.

Negatives

• The FDA has extended the review period by three months, delaying the potential approval of DCCR.
• The extension was due to a major amendment to the NDA, indicating that the initial submission was not complete.

Risks

• The FDA review process is subject to risks and uncertainties, and the approval of DCCR is not guaranteed.
• Market conditions and other factors could impact the commercial success of DCCR.
• The company's business is subject to risks and uncertainties described in their SEC filings.

Future Outlook

The company is focused on the FDA review process and determining a path forward for DCCR for the treatment of PWS, but the timing of any regulatory process or ultimate approvals is uncertain.

Management Comments

• Soleno Therapeutics announced that the FDA has extended the review period for the NDA for DCCR.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for rare diseases. The delay in the FDA review process is a common occurrence in the industry and highlights the challenges of bringing new drugs to market.

Comparison to Industry Standards

• The FDA's extension of the review period is not uncommon for NDAs, especially when major amendments are required.
• Other companies developing treatments for rare diseases, such as Ultragenyx and BioMarin, have also experienced similar delays in their regulatory processes.
• The granting of Priority Review and Breakthrough Therapy designations for DCCR is a positive sign, as these are often given to drugs that address unmet medical needs.

Stakeholder Impact

• Shareholders may react negatively to the delay in the FDA review process.
• Patients and families affected by Prader-Willi syndrome will have to wait longer for a potential treatment option.
• The company's employees may experience uncertainty due to the delay.

Next Steps

• The company will continue to work with the FDA to complete the review process for DCCR.
• The company will await the FDA's decision on the NDA by the new target action date of March 27, 2025.

Key Dates

Keywords

DCCR, Prader-Willi Syndrome, FDA, NDA, Diazoxide Choline, Hyperphagia, PDUFA, Soleno Therapeutics, Rare Diseases, Drug Approval